NCT03217747View on ClinicalTrials.gov

Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

173

Participants

Timeline

Start Date

August 2, 2017

Primary Completion Date

September 2, 2025

Study Completion Date

April 30, 2026

Conditions
Advanced Malignant Solid NeoplasmCastration-Resistant Prostate CarcinomaMalignant Solid NeoplasmMetastatic Malignant Solid NeoplasmMetastatic Prostate CarcinomaProstate Carcinoma Metastatic in the BoneRefractory Malignant Solid NeoplasmStage IV Prostate Cancer AJCC v8Stage IVA Prostate Cancer AJCC v8Stage IVB Prostate Cancer AJCC v8
Interventions
DRUG

Avelumab

Given IV

BIOLOGICAL

Ivuxolimab

Given IV

RADIATION

Radiation Therapy

Undergo radiation therapy

BIOLOGICAL

Utomilumab

Given IV

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER

NCT03217747 - Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies | Biotech Hunter | Biotech Hunter